Mylan Taking Immediate Action to Further Enhance Access to EpiPen(R) (Epinephrine Injection, USP) Auto-Injector Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients Company to cover up to 0 of out-of-pocket cost at pharmacy; reducing patient cost by 50% off Mylan list price Mylan also to open pathway to provide EpiPen® Auto-Injector directly to patients
PRNewswire/ -- Mylan N.V. ( NASDAQ , TASE: MYL) today announced it is taking immediate action to further enhance access to EpiPen® (epinephrine injection, USP) Auto-Injector by expanding already existing programs in recognition of those patients who are facing the burden of higher out-of-pocket costs. The company is reducing the patient cost of EpiPen® Auto-Injector through the use of a savings card which will cover up to 0 for their EpiPen 2-Pak®. For patients who were previously paying the full amount of the company's list price for EpiPen®, this effectively reduces their out-of-pocket cost exposure by 50%. Mylan also is doubling the eligibility for its patient assistance program, which will eliminate out-of-pocket costs for uninsured and under-insured patients and families as well. Mylan CEO Heather Bresch said, "We have been a long-term, committed partner to the allergy community and are taking immediate action to help ensure that everyone who needs an EpiPen® Auto-Injector gets one. We recognize the significant burden on patients from continued, rising insurance premiums and being forced increasingly to pay the full list price for medicines at the pharmacy counter. Patients deserve increased price transparency and affordable care, particularly as the system shifts significant costs to them. However, price is only one part of the problem that we are addressing with today's actions. All involved must also take steps to help meaningfully address the U.S. healthcare crisis, and we are committed to do our part to drive change in collaboration with policymakers, payors, patients and healthcare professionals." Mylan has worked to help patients with commercial insurance pay as little as !slideshow_deploy! for EpiPen® Auto-Injector using the My EpiPen Savings Card®. In 2015, this resulted in nearly 80% of these patients paying nothing out of pocket for their EpiPen® Auto-Injector. However, as the health insurance environment has evolved, driven by the implementation of the Affordable Care Act, patients and families enrolled in high deductible health insurance plans, who are uninsured, or who pay cash at the pharmacy, have faced higher costs for their medicine. Mylan is taking the following immediate actions to help further address the needs of patients and families: For patients in health plans who face higher out-of-pocket costs, the company is providing immediate relief by offering a savings card for up to 0 . This will effectively reduce by 50% the cost exposure for patients who would have otherwise paid the full list price for EpiPen® Auto-Injector. Mylan also is doubling eligibility for our patient assistance program to 400% of the federal poverty level. This means a family of four making up to ,200 would pay nothing out of pocket for their EpiPen® Auto-Injector. Further, Mylan will continue to offer the EpiPen4Schools® program. The program, launched in August 2012 , has provided more than 700,000 free epinephrine auto-injectors and educational resources to more than 65,000 schools nationwide to help them be prepared for anaphylaxis events among students. Mylan also is opening a pathway so that patients can order EpiPen® Auto-Injector directly from the company, thereby reducing the cost. These programs will apply to EpiPen® and EpiPen Jr® (epinephrine injection, USP) Auto-Injectors. In the interest of fostering greater price transparency in the healthcare system, Mylan is providing the entire economic story of the EpiPen® supply chain on our website. The Entire Economic Story of the U.S. Pharmaceutical Supply Chain
PRNewswire/ - BirchBioMed Inc. announced today that a unique and ground-breaking topical treatment developed by University of British Columbia (UBC) researchers to prevent scarring has completed a Health Canada approved Phase I trial.
PRNewswire-USNewswire/ -- A new group of patients suffering from aortic stenosis is now eligible for a minimally invasive aortic valve replacement. The U.S. Food and Drug Administration (FDA) has approved an expanded indication for the Sapien XT and Sapien 3 transcatheter heart valves for patients with severe symptomatic aortic valve stenosis who are at intermediate risk for death or complications associated with open-heart surgery. These devices were previously approved only in patients at high or greater risk for death or complications during surgery. Morton Plant Hospital has been participating in the FDA trial for intermediate risk patients since 2012.
Örebro University has been awarded SEK 11 million and will together with Senzime, Sandvik, Techtum and Nanoxis explore why the immune system reacts differently in different people after an operation, during an infection or because of polluted air.The so-called inflammasome is a relatively newly discovered protein complex, which has a key role in the immune system, is a cellular engine that helps the body's immune system to detect various substances that can be a threat and protect the body against infections. One in three people have inflammasomes that are easily triggered. This risk factor, which drives an inflammatory process, can affect some people when other are not; their immune system overreacts and become harmful. The collaboration with Örebro University seeks to explain how inflammasomes work in different medical situations, with different stimuli and in different individuals.
Pfizer To Acquire Small Molecule Anti-Infective Business From AstraZeneca
Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States. The agreement includes the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™(meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets aztreonam-avibactam (ATM-AVI) and CXL. Zavicefta specifically addresses multi-drug resistant Gram-negative infections, including those resistant to carbapenem antibiotics, one of the most significant unmet medical needs in bacterial infections treated with hospital anti-infectives.
Ohio Drug Price Ballot Measure: Advocates Submit 19,000 Voter Signatures, Far More than 5,044 Needed
COLUMBUS, Ohio--(BUSINESS WIRE)--In response to ongoing legal wrangling over a proposed Ohio ballot measure that would lower drug prices for state programs in Ohio, attorneys for the backers of the measure, known as the Ohio Drug Price Relief Act, today filed over 19,000 additional voter signatures in support of the measure, which backers intend to get placed on the November 2017 statewide ballot.
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it will launch “Chocola BB® Mouth Ulcer Repair Shot” (Third-class OTC drug) for mouth ulcers in Japan on Thursday, August 25. The product is the first oral care spray to be marketed under the Chocola BB brand.Mouth ulcer is a general term that refers to any inflammation of the mucous membrane in the mouth. In many cases, it is thought that nutritional imbalances, lifestyle changes and/or stress lead to a decrease in the mucous membrane's ability to regenerate, allowing bacteria to penetrate the membrane and cause an ulcer to form.
Lipoprotein(a) Foundation and European Atherosclerosis Society Partner to Raise Awareness of Inherited Cardiovascular Disease and Support Lp(a) Treatment Research
ROME--(BUSINESS WIRE)--The Lipoprotein(a) Foundation announced today that it has entered into an official partnership with the European Atherosclerosis Society (EAS) to raise awareness for inherited cardiovascular disease and the significance of high Lipoprotein(a) as an independent, genetic risk factor for early cardiovascular disease. The announcement was made here at the European Society of Cardiology (ESC) Congress 2016, August 27-31, 2016.
OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) today announced the launch of a bold, new Access to Medicines (AtM) strategy, aimed at increasing access to its innovative and potentially life-saving medicines for patients with some of the highest unmet medical needs. For decades, the company has provided product, funding and access in many parts of the world, based on regional needs. The new AtM strategy builds on that by focusing on geographies and therapy areas with the highest unmet need.
SciBase: New Study: Swedish Nevisense Can Reduce Follow-up Visits by Half for Difficult-to-Diagnose Lesions in Melanoma Detection
A new Australian study, using the Swedish instrument Nevisense, showed it is possible to reduce the number of cases that require digital dermoscopy follow-up by almost half. In addition Nevisense detected most melanoma three months earlier than traditional methods. Nevisense thereby constitutes a valuable complement to a visual exam with a dermatoscope. The study consisted of 118 patients with 160 lesions, and the results will be presented for the first time at the World Congress on Cancers of the Skin in Vienna on September 1.